Organoplatinum Compounds

• 

  Subject Areas on Research

  • A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. 
  • A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. 
  • A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. 
  • A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. 
  • Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis. 
  • Acute pain associated with oxaliplatin infusion: case report and literature review. 
  • Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. 
  • An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). 
  • Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). 
  • Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 
  • Chemotherapy and cancer stem cells. 
  • Colon cancer with microsatellite instability in a 13-year-old Hispanic male. 
  • Colon cancer, version 3.2014. 
  • Combined modality treatment for rectal cancer. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. 
  • Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. 
  • Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. 
  • Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1. 
  • Coordination-induced formation of submicrometer-scale, monodisperse, spherical colloids of organic-inorganic hybrid materials at room temperature. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin. 
  • Cyclization/hydrosilylation of functionalized 1,6-diynes catalyzed by cationic platinum complexes containing bidentate nitrogen ligands. 
  • Cyclization/hydrosilylation of functionalized diynes catalyzed by a cationic platinum phenanthroline complex. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. 
  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. 
  • ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. 
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. 
  • Factors influencing hyperthermic enhancement of drug cytotoxicity. 
  • Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. 
  • Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta. 
  • Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. 
  • Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. 
  • High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. 
  • Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. 
  • Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. 
  • Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. 
  • Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. 
  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. 
  • Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. 
  • Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. 
  • Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. 
  • Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. 
  • Physical activity among adult survivors of childhood lower-extremity sarcoma. 
  • Platinum-catalyzed intramolecular hydroamination of unactivated olefins with secondary alkylamines. 
  • Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathy. 
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. 
  • Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. 
  • Quantitative estimation of the thermal dose-modifying factor for cis-diamminedichloroplatinum (CDDP) in tumour-bearing dogs. 
  • RAD52 variants predict platinum resistance and prognosis of cervical cancer. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Rapid photothermal intracellular drug delivery using multiwalled carbon nanotubes. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Successful desensitization to oxaliplatin. 
  • Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. 
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. 
  • The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. 
  • Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. 
  • Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Professor of Medical Oncology, Medicine, Medical Oncology
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology